HBV基因组常见突变及临床意义

胡爱荣; 胡婷

doi:10.3969/j.issn.1001-5256.2016.08.006

HBV基因组常见突变及临床意义

DOI: 10.3969/j.issn.1001-5256.2016.08.006

胡爱荣,
胡婷

宁波市第二医院肝病中心宁波大学医学院

基金项目:

浙江省医药卫生省部培育计划项目(2014PYA018)；宁波市科技计划社发重大项目(2016C51005)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2494
- HTML全文浏览量: 53
- PDF下载量: 553
- 被引次数: 0
出版历程
- 收稿日期: 2016-05-20
- 出版日期: 2016-08-20

Common mutations of hepatitis B virus and their clinical significance

Hu AiRong,
Hu Ting

Liver Disease Center,Ningbo No.2 Hospital,Ningbo University School of Medicine

Research funding:

摘要

摘要: HBV基因组特殊的结构及生活周期特点决定了其易于突变。突变改变了病毒的生物学行为和对抗病毒药物的敏感性,影响治疗效果和疾病的进展。前S/S开放读码框（ORF）以点突变为主,可引起免疫逃避,与隐匿性HBV感染有关;前C/C-ORF以G1896A突变常见,与HBe Ag阴性慢性乙型肝炎（CHB）、肝细胞癌（HCC）、慢性重型肝炎（肝衰竭）的发生相关;P-ORF的突变主要发生在逆转录酶区（RT区）,与核苷和核苷酸类药物的耐药关系密切;X-ORF突变主要是重叠于该区的核心启动子的A1762T和G1764A的双突变,与HBe Ag阴性CHB、HCC、慢性重型肝炎（肝衰竭）相关。明确这些突变与疾病的关系,可为HBV感染者制订个体化的诊疗方案。
- 肝炎病毒,乙型 /
- 基因组 /
- 突变 /
- 抗药性
Abstract: Hepatitis B virus( HBV) tends to mutate easily due to its special structure and life cycle. Mutation changes the biological behavior of HBV and its sensitivity to antiviral drugs and even affects therapeutic effect and accelerate disease progression. The point mutations are commonly see in the pre- S / S open reading frame( ORF),which may be associated with immune escape and occult HBV infection. The G1896 A mutation is often observed in the pre- C / C- ORF and is associated with the development of HBe Ag- negative chronic hepatitis B( CHB),hepatocellular carcinoma( HCC),and severe chronic hepatitis( liver failure). The mutations in P- ORF mainly occur in the reverse transcriptase( RT) domain and are closely related to the resistance to nucleos( t) ide analogues. The A1762 T and G1764 A mutations occur in the basal core promoter( BCP),which overlaps with X- ORF,and may be associated with HBe Ag- negative CHB,HCC,and severe chronic hepatitis( liver failure). Clarification of the association between these mutations and diseases helps to develop tailor- made diagnostic and therapeutic regimens for patients with HBV infection.
- hepatitis B virus /
- genome /
- mutation /
- drug resistance

HTML全文

参考文献(26)

[1]World Health Organization.Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection[EB/OL].[2016-05-12].http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/.

[2]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.

[3]WANG FS,FAN JG,ZHANG Z,et al.The global burden of live disease:the major impact of China[J].Hepatology,2014,60(6):2099-2108.

[4]BISWAS S,CANDOTTI D,ALLAIN JP.Specific amino acid substitutions in the S protein prevent its excretion in vitro and may contribute to occult hepatitis B virus infection[J].J Virol,2013,87(14):7882-7892.

[5]CHEN JH,LIU Y,LI J,et al.Occult hepatitis B virus infection:Present and future[J].J Prac Hepatol,2015,18(2):205-208.(in Chinese)陈建宏,刘妍,李进,等.隐匿性乙型肝炎病毒感染研究进展[J].实用肝脏病杂志,2015,18(2):205-208.

[6]HUANG CH,YUAN Q,CHEN PJ,et al.Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors[J].J Hepatol,2012,57(4):720-729.

[7]KIM BK,CHOI SH,CHUNG SH,et al.Pre-S mutations of hepatitis B virus affect genome replication and expression of surface antigens[J].J Gastroenterol Hepatol,2014,29(4):843-850.

[8]LEE SA,KIM KJ,KIM DW,et al.Male-specific W4P/R mutationin the pre-S1 region of hepatitis B virus,increasing the risk ofprogression of liver diseases in chronic patients[J].J Clin Microbiol,2013,51(12):3928-3936.

[9]YEUNG P,WONG DK,LAI CL,et al.Association of hepatitis Bvirus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B[J].J Infect Dis,2011,203(5):646-654.

[10]ZHAND S,KARAMI C,HOSSEINZADEH ADLI A,et al.Correlation between hepatitis B G1896A precore mutations and HBeA g in chronic HBV patients[J].Jundishapur J Micmbiol,2015,8(2):e17126-e17129.

[11]ZHANG XY,ZHU XQ,ZHENG WW.Correlation between X/preCregion mutations in hepatitis B virus genotype C and hepatocellular carcinoma[J].Inter J Epidemiol Infect Dis,2014,41(3):172-175.(in Chinese)张宣义,朱小区,郑伟伟.乙型肝炎病毒C型X/preC区突变与原发性肝癌的相关性研究[J].国际流行病学传染病学杂志,2014,41(3):172-175.

[12]ZHENG D,DENG W,HUANG TR,et al.Relationship between hepatitis B virus genotype,BCP/Pre-C region mutations and risk of hepatocellular carcinoma in Guangxi Zhuang Autonomous Region[J].Chin J Epidemiol,2015,36(7):725-729.(in Chinese)郑丹,邓伟,黄天壬,等.广西壮族自治区肝癌高发区HBV基因型、BCP/前C区突变与肝癌相关性的研究[J].中华流行病学杂志,2015,36(7):725-729.

[13]FU LJ,CHEN Y,ZHANG Y,et al.Clinical significance of hepatitis Bvirus(HBV)precore and core promoter mutations affecting HBV e-antigen expression and their association with liver disease progression[J].Chin J Physician,2014,16(6):721-723.(in Chinese)付丽娟,陈颖,张怡,等.肝脏疾病进展与乙型肝炎病毒前C/C区突变[J].中国医师杂志,2014,16(6):721-723.

[14]BWSHARAT S,POUSTCHI H,MOHAMADKHANI A,et al.Association of mutations in the basal core promoter and pre-core regions of the hepatitis B viral genome and longitudinal changes in HBV level in HBeA g negative individuals:results from a cohort study in northern Iran[J].Hepat Mon,2015,15(2):e23875.

[15] Experts Attending the Disscussion on Hepatitis B Virus Drug Resistance.Drug resistance to nucleoside and nucleotide analogs in chronic hepatitis B and its management[J].Infect Dis Info,2013,26(1):1-9.(in Chinese)参加乙型肝炎耐药讨论会专家.核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理[J].传染病信息,2013,26(1):1-9.

[16]JIANG SW,YAO LP,HU AR,et al.Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates[J].World J Gastroenterol,2014,20(45):17100-17106.

[17]HU AR,JIANG SW,LI L,et al.Clinical analysis of hepatitis Bvirus mutations related to adefovir dipivoxil among patients with chronic hepatitis B virus infection in eastern Zhejiang province[J].Natl Med J China,2012,92(27):1878-1881.(in Chinese)胡爱荣,蒋素文,李玲,等.浙江省东部地区慢性乙型肝炎病毒感染者阿德福韦酯相关位点病毒变异的临床特征分析[J].中华医学杂志,2012,92(27):1878-1881.

[18]ISMAIL AU,SHARMA OP,KUMAR MS,et al.Impact of rtI 233Vmutant in hepatiits B virus polymerase protein and adefovir efficacy:homology modeling and molecular docking studies[J].Bioinformation,2013,9(3):121-125.

[19]QIN B,BUDEU P,CAO L,et al.The amino acid substitution rtP 177G and rtF 249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir[J].Antiviral Res,2013,97(2):93-100.

[20]GAO GS,WENG PJ,XU XM,et al.Hepatitis B virus(HBV)gene mutations related to entecavir-resistance in patients with chronic HBV infections[J].Chin J Clin Infect Dis,2015,8(2):139-142.(in Chinese)高国生,翁彭剑,许小敏,等.慢性HBV感染者恩替卡韦耐药突变特征分析[J].中华临床感染病杂志,2015,8(2):139-142.

[21]XU ZJ,PAN XN,YANG HW,et al.Study on primary drug resistance mutation in the reverse transcriptase region of hepatitis B virus[J].Chin J Gastrol Hepatol,2012,21(10):927-929.(in Chinese)许正锯,潘兴南,杨环文,等.乙型肝炎病毒RT区原发性耐药变异的研究[J].胃肠病学和肝脏病学杂志,2012,21(10):927-929.

[22]MAO HF,HU AR,JIANG SW,et al.Pathogenic and clinical characteristics of hepatitis B virus(HBV)pre-existing mutations related to adefovir dipivoxil(ADV)among ADV treatment-naive patients with chronic HBV infection[J].China Preven Med,2013,14(1):55-58.(in Chinese)毛海芳,胡爱荣,蒋素文,等.阿德福韦酯相关位点预存病毒变异的病原学及临床特征分析[J].中国预防医学杂志,2013,14(1):55-58.

[23]CALIGIURI P,CERRUTI R,ICARDI G,et al.Overview of hepatitis B virus mutations and their implications in the management of infection[J].World J Gastroenterol,2016,22(1):145-154.

[24]XU C,ZHOU W,WANG Y,et al.Hepatitis B virus-induced hepatocellular carcinoma[J].Cancer Lett,2014,345(2):216-222.

[25]DONG H,XU Y,LIU LQ,et al.Mutation analysis of hepatitis Bvirus X gene in hepatitis B virus-associated glomerulonephritis[J].Chin J Nephrol,2014,30(4):273-278.(in Chinese)董晖,徐岩,刘丽秋,等.乙型肝炎病毒相关性肾小球肾炎患者病毒X基因变异分析[J].中华肾病杂志,2014,30(4):273-278.

[26]LEI M,HE S.Study of HBV-X gene mutation among patients with HBV-related chronic hepatitis,liver cirrhosis,and primary liver cancer[J].J Clin Hepatol,2014,30(6):531-536.(in Chinese)雷蔓,何松.慢性乙型肝炎、乙型肝炎肝硬化及原发性肝癌患者HBV-X基因突变分析[J].临床肝胆病杂志,2014,30(6):531-536.

施引文献

资源附件(0)

访问统计